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Abstract
Over the past two decades a number of severe acute respiratory
infection outbreaks such as the 2009 influenza A (H1N1) and the
Middle East respiratory syndrome coronavirus (MERS-CoV) have
emerged and presented a considerable global public health threat.
Epidemiologic evidence suggests that diabetic subjects are more sus-
ceptible to these conditions. However, the prevalence of diabetes in
H1N1 and MERS-CoV has not been systematically described. The aim
of this study is to conduct a systematic review and meta-analysis of
published reports documenting the prevalence of diabetes in H1N1
and MERS-CoV and compare its frequency in the two viral conditions.
Meta-analysis for the proportions of subjects with diabetes was carried
out in 29 studies for H1N1 (n=92,948) and 9 for MERS-CoV (n=308).
Average age of H1N1 patients (36.2±6.0 years) was significantly
younger than that of subjects with MERS-CoV (54.3±7.4 years,
P<0.05). Compared to MERS-CoV patients, subjects with H1N1 exhib-
ited 3-fold lower frequency of cardiovascular diseases and 2- and 4-fold
higher prevalence of obesity and immunosuppression, respectively.
The overall prevalence of diabetes in H1N1 was 14.6% (95% CI: 12.3-
17.0%; P<0.001), a 3.6-fold lower than in MERS-CoV (54.4%; 95% CI:
29.4-79.5; P<0.001). The prevalence of diabetes among H1N1 cases
from Asia and North America was ~two-fold higher than those from
South America and Europe. The prevalence of diabetes in MERS-CoV
cases is higher than in H1N1. Regional comparisons suggest that an
etiologic role of diabetes in MERS-CoV may exist distinctive from that
in H1N1.
Introduction
For the past two decades, pandemics of severe acute respiratory
infections (SARI) have been serious threats to global health, causing
significant morbidity and mortality. Reassorted novel strains of
influenza viruses and coronaviruses continue to arise, rendering vac-
cinations - if developed - less useful and posing increased risks to
humans. Two prominent viruses – 2009 influenza A (H1N1) and the
Middle East respiratory syndrome coronavirus (MERS-CoV) – have
markedly affected humans. H1N1, since the 2009 pandemic, has
caused about 284,500 deaths, both directly via respiratory infections
and indirectly from the cardiovascular diseases secondary to bacterial
infections.1 In addition, MERS-CoV, since its first emergence in 2012,
has infected 1600 individuals, causing 574 deaths and was reported in
26 countries although the vast majority of reported cases originated
from the Arabian Peninsula.2
H1N1 and MERS-CoV both target the respiratory tract, and share
many similar clinical symptoms. The most common symptoms are
fever, cough, shortness of breath, and sore throat3-8 followed always by
gastrointestinal symptoms such as nausea, vomiting, and diarrhea.3,7-
9 Both diseases often lead to complications such as pneumonia, acute
respiratory distress syndrome, organ failure, and even death.4,6,9
Complications mostly lie within the respiratory system with organ fail-
ure commonly noted in the respiratory system, followed by renal and
cardiovascular systems.5 Individuals infected with H1N1 usually
belong to those aged between 21 and 50 years,4,5 and have a mean age
in the early 40s.3,5 MERS-CoV, on the other hand, mostly infects older
adults with a median age of 50 years.10 This difference was hypothe-
sized to be related to the development of cross-reactive antibodies
against influenza viruses from previous exposures to seasonal influen-
za in elder people.5 Another difference between H1N1 and MERS-CoV
relates to the length of the incubation period. H1N1 has a short incu-
bation period between 1 and 2 days,11 whereas MERS-CoV has a much
longer period of ~5 days.10
Many infected individuals exhibit comorbidities (e.g., diabetes,
hypertension, asthma, and obesity), rendering them more susceptible
to complications.3-7 Diabetes is one of the known documented con-
tributing host-related risk factor in both H1N1 and MERS-CoV severe
cases, and is frequent in individuals developing fatal disease compli-
cations.4-7 This observation may suggest an etiological relationship
between diabetes and acute viral respiratory infections. Diabetes and
its related conditions downregulate the innate and humoral immune
systems by reducing the function of T cells and neutrophils.12
Hyperglycemia impairs critical components of innate immunity in
vitro, such as chemotaxis, phagocytosis, and the bactericidal activity of
neutrophils and macrophages and lead to secondary infections.13 The
direct influence of diabetes, however, on acute respiratory infections
Significance for public health
Outbreaks of the 2009 influenza A (H1N1) and the Middle East respira-
tory syndrome coronavirus (MERS-CoV) have presented a considerable
global public health threat over the past few years. Evidence suggest
that infected subjects who are also diabetic are more likely to be suscep-
tible to severe outcome of H1N1 and MERS-CoV. Systematic analysis of
~93,000 H1N1 cases and ~300 MERS-CoV cases indicated an overall
prevalence of 14.6% and 54.4% for diabetes in H1N1 and MERS-CoV
cases, respectively. This may suggest a possible etiological relationship
between diabetes and each of the two infectious conditions.
Introduction of effective public health vaccination intervention strate-
gies against severe acute respiratory infections should be developed to
target subjects with chronic disorders such as diabetes, obesity and car-
diovascular conditions.
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still needs more research to estimate the frequency of diabetes in
severe viral conditions and to elucidate the etiologic role on diabetes in
disease severity.14 The present study was undertaken to conduct a sys-
tematic review and meta-analysis of published literature to describe
the prevalence of diabetes in two of the emerging severe acute respira-
tory infections such as H1N1 and MERS-CoV and to explore its possible
contribution to the severity and complication of the two viral condi-
tions.
Materials and MethodsSearch strategy and selection criteria 
A search was conducted in PubMed, Ovid MEDLINE, Embase and
Embase Classic databases to the last week of July 2015 using the
search terms (MeSH) H1N1 or MERS-CoV (Middle East respiratory syn-
drome coronavirus) and Diabetes. The search resulted in 123 articles
selected for title and abstract review as they satisfied our selection cri-
teria (see below). We limited the studies into those in humans and
excluded reports published as review articles, letters, case studies, edi-
torials, conference abstracts, vaccination trials or family-based studies.
After eliminating duplicate listings and only considering articles in full
text, a total of 44 peer-reviewed original studies were selected for full
text review. Full article review resulted in the further exclusion of 8
reports that were not documenting the prevalence of diabetes in H1N1
or MERS-CoV (i.e., no association studies), examining only a small
number of travellers as a case report (n=2 subjects), reporting season-
al influenza alone, reviewing already reported cases (MERS-CoV), or
simply documenting national surveys. A bibliography search of the
remaining articles identified two additional studies. A total of 38 peer-
reviewed articles (29 studies for H1N13-5,14-39 and 9 for MERS-CoV6-9,40-
44) were identified for this article (Figure 1). 
Inter-reviewer agreement
The abstracts of the identified studies were independently reviewed
by two readers (AB and SJ). Differences were resolved through discus-
sions for a consensus to be reached. Percentage agreement and
Cohen’s Kappa (k) statistic45 were calculated and interpreted in accor-
dance with Landis and Koch’s benchmarks46 for assessing the agree-
ment between reviewers as poor (<0), slight (0.0-0.20), fair (0.21-
0.40), moderate (0.41-0.60), substantial (0.61-0.80), and excellent
(0.81-1.0). The agreement on the inclusion between the two reviewers
was 86%, with k=0.72 (95% CI 0.58-0.85). Quality score assessment
The methodological quality of each study was evaluated as previously
described47 with some modification. Quality of the study was based on
four criteria: (a) the number of study subjects (n; at least the median
of 157 for H1N1 and 17 for MERS-CoV), (b) comprehensive reporting of
patients’ demographic information, (c) describing a minimum of 3 dis-
ease-associated symptoms and (d) reporting at least 2 comorbidities
(in addition to diabetes). For each criterion, each study was given a
score (0 or 1, with 1 fulfilling the criteria). The total score was calcu-
lated for each study (score range 0-4). Quality scores of 1, 2, 3, and 4
were considered poor, fair, good and very good, respectively.Data extraction and analysis
Data extracted from the selected studies included the first author’s
name, publication date, country, dates of recruitment, ethnicity, total
sample size (divided to males and females), age, prevalence of symp-
toms (including fever, shortness of breath, sore throat, cough and Acute
Physiology and Chronic Health Evaluation II, APACHEII) and percentage
of comorbidities at the time of presentation (including obesity,
immunosuppression or HIV and heart conditions such as hypertension,
cardiovascular diseases and/or coronary arterial diseases) (Tables 1 and
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Figure 1. Systematic literature review process. The flow diagram describes the systematic review of literature on the contribution of dia-
betes to severe H1N1 and MERS-CoV. A total of 38 unique studies were identified (29 studies for H1N1 and 9 for MERS-CoV from
an initial 342 examined titles).
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2). Weighted average was used to calculate the average age and the
overall prevalence of clinical symptoms and comorbidities. Publication
bias was assessed both by the visual inspection of funnel plot (Figure 2)
and by Egger’s test. Egger’s test is widely used to assess the tendency for
the effects estimated in small sample size studies to differ from those
estimated in larger studies. The results of Egger’s test are presented in
terms of bias coefficient. To measure the prevalence of diabetes in the
two viral conditions, we extracted the proportion of the disease in the
reported cases of severe respiratory infections. A subgroup analysis was
carried out by region, only for the H1N1 studies (Table 3). Region sub-
group analysis for MERS-CoV was not doable since all the identified
studies were conducted on Saudi populations, with one study of pooled
analysis where region/country designation was not possible. The pri-
mary outcome measure was to evaluate the prevalence of diabetes in
H1N1 and MERS-CoV cases. The meta-analysis of proportions (and 95%
CIs) was calculated for the identified studies (Figure 3) and in a sub-
group analysis within each region (Table 3). Meta-analysis tests were
conducted using the OpenMeta Analyst version 10.10, a free, cross-plat-
form, open-source program.48 We used binary random-effects model
since we assumed that the relationship between diabetes and severe
respiratory infection is varied across populations. T-test was used to
compare between average age in H1N1 and MERS-CoV since this factor
was normally distributed in the two sets of studies. Mann-Whitney U-
test was employed to compare the prevalence of clinical symptoms and
comorbidities between the two diseases as these conditions were not
normally distributed. To assess whether there is true heterogeneity
among the selected studies and that all the studies are evaluating the
same effect, we used the Q test.49 Q test only informs about the presence
versus the absence of heterogeneity and does not report on the extent
of such heterogeneity. Therefore, we calculated the I2 index to comple-
ment the Q test and quantify the degree of heterogeneity among stud-
ies.50 Given the poor power of Q test to detect true heterogeneity among
a small number of studies, we also quantified the true heterogeneity by
estimating the between-study variance in the random-effects model
(τ2), as previously described.51 P<0.05 was considered to be statistically
significant. Forest plots were used to illustrate the prevalence of dia-
betes in H1N1 and MERS-CoV severity from the selected studies and to
inspect the heterogeneity of the individual findings. 
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Table 1. Characteristics of the H1N1 identified studies.
Study                                 Country      Dates,                         N                         Age            Symptoms                      Comorbidities     Quality 
                                                              mm.yy         All            M             F          (yr)                                         (%)                            (%)                 Score
                                                                             (92,948) (46,181) (46,351)              APACHEII   Fever    Shortness    Sore   Cough     Obesity    HT/     Imm/
                                                                                                                                                                         of Breath   Throat                                 CAD/     HIV
                                                                                                                                                                                                                                          CVD        
Al-Soub et al. 20143                                Qatar           07.09-01.11            40                  24                  16               42.7                 12                  90                     75                    23               88                    28               40              3               3
Allam et al., 20134                                    India            05.09-12.10            45                  24                  21                                                              18                     80                    16                                                           18              3               2
Bagshaw et al., 201315                                 Canada         04.09-04.10           562                262                300               48                  21                                                                                                               27                                                   2
Balaganesakumar et al., 201316            India            01.10-12.10            72                  41                  31               45.5                                       96                     85                    60               88                    24                                  9               3
Chawla et al., 20135                                 India            10.09-12.10            77                  44                  33               40.9                                       97                     77                    33               87                                        25              8               3
Jimenez-Garcia et al., 201317               Spain           01.09-12.09        11,499            5806              5693             39.6                                                                                                                                     9                 2               2               3
Kusznierz et al., 201318                      Argentina       05.09-07.09           242                121                121              33.7                                       72                     71                                       88                    16               33              3               4
Suryaprasad et al., 201319                   USA-AB         05.09-07.09            88                  31                  57                37                                                                   9                                                                 71                8               4               2
Vallejos et al., 201320                          Argentina       05.09-08.09            44                  25                  19               49.5                                                                91                                                                25               34                                2
Aziz-Baumgartner et al., 201221       Argentina       04.09-12.09            49                  27                  22                37                                                                                                                                      53                                                   1
Chowell et al., 201222                            Mexico         08.09-12.09          3456              1482              1974              22                                       79.9                   57                    56               84                    12                                  5               4
Delgada-Rodriguez et al., 201223         Spain           07.09-02.11           813                403                410              38.5                                                                                                                                                         9                                 2
Cortes-Garcia et al., 201214                  Spain           06.09-12.09          2413              1246              1167             42.5                                                                                                                                    22               29             12              3
Marija Kojicic et al., 201224                    BAH            11.09-03.10            50                  31                  29                43                  19                                           16                                                                64                5               6               2
Miller et al., 201225                                   USA            05.09-06.09            43                   8                   35               36.4                                       60                     63                    16               73                                                           7               2
Wane et al., 201226                                Rwanda         10.09-05.10           532                257                275               42                                         85                     33                    58               88                                         2                                 3
Chudasama et al., 201127                       India            09.09-02.10           274                141                133              29.5                                       92                     53                    54               97                                         9               5               4
Gilca et al., 201128                                  Canada         04.09-06.09           321                154                167               29                                                                                                                                      25               13              8               3
Ward et al., 201129                                Australia        07.09-08.09           302                125                177               45                                                                                                                                      35               14             10              3
Yokota et al., 201130                                Brazil                 07.09                157                 78                  79                33                                         97                     97                    47               99                    38                6               9               4
Van Kerkhove et al., 201131                 Pooled          04.09-01.10        70,000           35,140           34,860             36                                                                                                                                       6                 7               5               3
Allard et al., 201032                                Canada         05.09-07.09           162                 73                  89               28.6                                                                                                                                                                                            2
Carcione et al., 201033                         Australia        05.09-08.09           871                427                444               26                                         88                     33                    56               85                     9                 5               3               4
Fajardo_Dolci et al., 201034                Mexico         04.09-05.09           100                 47                  53               54.5                                       84                     75                                       85                    14               18              2               3
Koegelenberg et al., 201035               S. Africa         08.09-09.09            19                   4                   15               39.5                 18                                                                                                               21                                 32              2
Venkata et al., 201036                               USA            05.09-12.09            66                  33                  33               46.9                                       83                     71                    21               88                    44               32             20              3
Xi et al., 201037                                         China           10.09-12.09           155                 90                  65                43                                         94                     47                    30               92                                        38                                2
CDC, 200938                                             USA-AB         04.09-12.09           416                                                           44.5                                                                                                                                                                                            1
Kwan-Gett et al., 200939                          USA            04.09-08.09            70                  37                  33                11                                                                                                                                      41               11             16              2
Total/Weighted Average (SD)                  -                04.09-02.11        92,948           46,181           46,351      36.2(6.0)      20.2(4.5)      82.5(9.1)        53.3(7.3)        38.9(6.2)  85.9(9.3)         7.7(2.8)     7.2(2.7)   4.8(2.2)         -
APACHEII, Acute Physiology and Chronic Health Evaluation II; HT, CAD, CVD, hypertension, coronary artery diseases, cardiovascular diseases; Imm, immunodeficiency. AB, Aboriginal; BAH, Bosnia and Herzegovina.
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Results
The present systematic review examines the relationship between
diabetes and the H1N1 and MERS-CoV. A total of 38 studies that report
the prevalence of diabetes in H1N1 (n=92,948 cases from 29 studies,
Table 1) and MERS-CoV (n=308 cases from 9 studies, Table 2) were
selected.  The funnel plot (Figure 2) demonstrated a non-symmetrical
distribution of the effect size of each study on either side of the pooled
estimate. This seemingly non-symmetrical appearance of the plot sug-
gested evidence of publication bias. Egger’s test also supported this
notion particularly in MERS-CoV studies where the bias coefficient was
not statistically significant - given the assumption for evidence of
small-study effects is based on P<0.1 (P=0.13 for the H1N1 studies and
P=0.065 for the MERS-CoV studies). These findings are supported by
the significant heterogeneity (P<0.001) among the selected studies
(see below). According to our quality scoring criteria (see above), the
majority of the studies were between fair (score 2; 12 reports) and good
(score 3, 16 reports) quality with 7 studies that fulfilled all quality scor-
ing criteria (score 4, very good). Within the selected studies, sex-ratio
(male:female) in the majority of the H1N1 reports was 1:1 whereas it
was ~2:1 in the MERS-CoV cases. The average age of H1N1 cases
(36.2±6.0 years, range: 11-54.5 years) was significantly younger than
MERS-CoV cases (54.3±7.4 years, range: 36-66 years, t-test P=0.0004).
The prevalence of fever, shortness of breath, sore throat and cough was
not statistically different between H1N1 and MERS-CoV cases from the
two sets of studies (Mann-Whitney U test at P<0.05). We observed a
non-statistically significant ~2-fold higher frequency of obesity (>30
kg/m2) in the MERS-CoV patients compared to their H1N1 counterparts
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Table 2. Characteristics of the MERS-CoV identified studies.
Study ID*                          Dates,                              N                       Age              Symptoms                      Comorbidities      Quality 
                                           mm.yy                 All         M          F          (yr)                                                (%)                              (%)                    Score
                                                                    (308)   (199)   (109)                    APACHEII      Fever     Shortness  Sore        Cough      Obesity     HT/    Imm/
                                                                                                                                                                               of Breath    Throat                       CAD/    HIV
                                                                                                                                                                                                                                       CVD        
Shalhoub et al., 201540                     04.14-06.14                       24               14              10                 66                                                  79                                             83                      88                                            75                                    3
Al-Tawfiq et al., 20149                      04.14-06.14                       17               11               6                  62                                                  40                      67                   7                       86                                            53                                    3
Al-Tawfiq et al., 201441                     04.14-06.14                        5                 3                2                 57.6                                                                                                                                                                            40                                    1
Arabi et al., 20146                              12.12-08.13                       12                8                4                  59                      28                       67                      92                   8                       83                                            93                                    3
Memish et al., 201442                       06.13-08.13                       12                6                6                  36                                                 100                    100                 80                     100                      8                   33                                    3
Assiri et al., 20137                             09.12-06.13                       47               36              11                64.5                                                87                      72                  21                      83                      17                  62                                    4
Assiri et al., 20138                             04.13-05.13                       23               17               6                  56                                                  87                      48                                            87                      24                  39              0                    4
Memish et al., 201343                                                                    7                 0                7                  43                                                  57                      57                                            29                                                                                    2
WHO, 201344                                       09.12-10.13                      161             104             57                 50                                                                                                                                                                             7.5             5                    3
Total/Weighted Average (SD)       09.12-06.14                      308             199            109          54.3(7.4)                28                 78.0(8.8)         70.6(8 .4)     37.1(6.1)          83.6(9.1)         17.6(4.2)     31.3(5.9)      4.4                   -
*All studies were from KSA, except WHO, 2013,44 examined samples pooled from France, Germany, Italy, Jordan, KSA, Qatar, Tunisia, UAE, UK. For abbreviation, see Table 1.
Table 3. Meta-Analyses for the prevalence of diabetes in severe H1N1 cases by region.
Region                                                       Number               Percent prevalence of diabetes            Heterogeneity Analysis
                                                                of subjects                        in H1N1(95% CI)                                            
                                                                                                                                                              τ2 Cochran’s Statistic       I2
                                                                                                                                                                                  Q                  P              
Europe14,17,23,24                                                               14,775                                           10.1 (8.5-11.5)                                   0.0                   11.5                  0.009           73.9
Asia3-5,16,27,29,33,37                                                              1,836                                           17.6 (12.1-23.1)                               0.005                 62.9                <0.001          88.9
Africa26,35                                                                            551                                            14.2 (-16.2-44.5)                               0.043                  8.6                   0.003           88.3
North America15,19,22,25,28,32,34,36,38,39                             5,294                                           19.7 (13.8-25.6)                               0.008                166.7               <0.001          94.6
South America18,20,21,30                                                    492                                               9.8 (4.4-15.3)                                  0.002                 11.7                  0.009           74.3
Figure 2. Funnel plot for systematic review on the prevalence of
diabetes in H1N1 and MERS-CoV studies. The logit event rate
for prevalence (horizontal axis) is presented against the standard
error (SE) of the log of logit event rate (vertical axis) for H1N1
(a) and MERS-CoV (b) studies. The SE inversely corresponds to
the study size. Asymmetry of the plot can indicate publication
bias. Open circles indicate the individual studies.
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(17.6±4.2 vs. 7.7±2.8%). The combined frequencies of cardiovascular
diseases, hypertension, and cardio-artillery diseases were ~3-fold
higher in MERS-CoV cases than in H1N1 (31.3±5.9% vs. 7.2±2.7,
P=0.0004). 
Meta-analyses for the proportion of diabetes in H1N1 and MERS-CoV
are shown in Figures 3 and 4, respectively. The overall proportion of
diabetes in H1N1 is 15% (95% CI: 12-17%), 3.6-fold lower than its pro-
portion in MERS-CoV (54%, 95%CI: 28-80%). The two sets of studies
displayed a significant heterogeneity (P<0.001) among the selected
studies (Q test: 1943 for H1N1 vs. 169.8 for MERS-CoV). Additionally,
the degree of heterogeneity among studies was statistically significant
(P<0.001) and comparable between the two sets of studies (I2 index:
98.6 for H1N1 vs. 95.3 for MERS-CoV). The between-study variance in
the random-effects model was markedly lower among the H1N1 studies
(τ2=0.003) than the MERS-CoV reports (τ2=0.134).
Subgroup analysis by region for H1N1 studies (Table 3) showed that
the frequency of diabetes in H1N1 from Asia and North America (~18-
20%, P<0.001) is 2-fold higher than its prevalence in the cases recruit-
ed from Europe and South America (~10%, P<0.001). Cases from
Africa (14%) showed a non-significant slightly lower diabetes preva-
lence compared to those from Asia and North America. It should be
noted however, that the frequency estimate from Africa was developed
only from two studies (compared to 8 and 10 studies from Asia and
North America, respectively, and 4 studies from each of Europe and
South America). The heterogeneity tests for the studies included in all
regional sub-analyses exhibited significant overall heterogeneity (Q
test, P≤0.009), degree of heterogeneity among studies (I2 index) and
between-study variance in the random-effects model (τ2 test).
Discussion
The present systematic review evaluates the frequency of diabetes in
SARI conditions such as H1N1 and MERS-CoV. We observed a large dif-
ference between the volume of literature and total number of subjects
evaluated for each condition and identified 29 studies for H1N1 (with
92,948 subjects) and 9 for MERS-CoV (with 308 patients). About 60% of
the selected studies (23 out of 38) had a quality score between good
and very good (Tables 1 and 2). This indicates that a large set of the
studies had a sufficient enough number subjects to substantiate the
outcome and have provided a comprehensive reporting of patients’
demographic information. Furthermore, the majority of the selected
studies reported a set of disease-associated symptoms and comorbidi-
ties that permitted developing a comprehensive profile of the infec-
tious disease and its complication. This difference reflects the discrep-
ancy between the two diseases in their global (H1N1) versus regional
(MERS-CoV) spread, and the period during which they emerged.
Immediately following its outbreak in 2009, the H1N1 triple reassortant
swine influenza viruses contained genes from avian, swine, and
human influenza A viruses53,54 and sustained a rapid between-human
transmission to spread globally.52 On the other hand, in 2012, the emer-
gence of MERS-CoV was to a great extent contained within the Arabian
Peninsula55 and dromedary camels were identified as the intermediate
host56 with a closely related virus sequences found in bats.57 Apart from
a number of nosocomial outbreaks involving healthcare workers caring
for MERS-CoV patients; little evidence has been initially reported for
sustained person-to-person transmission.58 However, during the 2015
MERS-CoV outbreak in the Republic of Korea it was demonstrated that
among 186 cases, 83.2% of the transmission events were linked to only
5 super-spreaders, all of whom had pneumonia at presentation and
contacted hundreds of people, adding evidence to the person-to-person
transmission in MERS-CoV.59
The characteristic pattern of transmission and spread of H1N1 and
MERS-CoV may have resulted in a distinctive sex-ratio for each condi-
tion. MERS-CoV cases exhibited a sex-ratio (male:female) of 2:1, twice
that noted for H1N1 cases (Tables 1 and 2). The male predominance of
MERS-CoV reflects the higher likelihood of exposure to the infectious
agent in males than in females in Middle Eastern cultures. In addition,
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Figure 3. Meta-analysis for the proportion of diabetes in H1N1
cases. Weights are calculated from binary random-effects model
analysis. Values represent proportion of diabetic cases in the
H1N1 patients and 95% CI. Heterogeneity analysis was carried
out using Q test, the among studies variation (I2 index) and in
between-study variance in the random-effects model (τ2).
Figure 4. Meta-analysis for the proportion of diabetes in MERS-
CoV cases. Weights are calculated from binary random-effects
model analysis. Values represent proportion of diabetic cases in
the MERS-CoV patients and 95% CI. Heterogeneity analysis was
carried out using Q test, the among studies variation (I2 index)
and in between-study variance in the random-effects model (τ2).
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most males who tested positive for the virus and died also had under-
lying medical conditions, which could explain the severity of cases in
older males.60 In agreement, MERS-CoV cases were significantly older
(54.3±7.4 years) than their H1N1 (36.2±6.0 years) counterparts. The
average age of H1N1 patients is similar to that in H5N1 cases where 90
percent of the subjects were 40 years or younger.61 As noted with H5N1
cases, it can be estimated that 15-20% of elder people may have resid-
ual immunity against this H1N1 flu strain following their life-time
exposures to multiple influenza outbreaks.61-64 This immunogenicity
does not apply to coronaviruses and may explain the younger average
age of H1N1 cases compared to MERS-CoV cases. Indeed, it was pro-
posed over 60 years ago that repeated exposures to antigenic variants
of influenza viruses may result in antibodies recognizing a large num-
ber of common flu antigens, and develop a reinforced immunity that
lower the risk of infection with newly emerging variants.65
The clinical presentations of SARI generally include respiratory
symptoms, such as fever, new onset or exacerbation of cough, breath-
ing difficulty and sore throat. Severe illnesses may vary from pneumo-
nia, acute respiratory distress syndrome, encephalitis, myocarditis, or
other severe and life-threatening complications.66 The frequency of
fever, shortness of breath, sore throat and cough was similar between
H1N1 and MERS-CoV cases. In contrast, underlying medical conditions
and comorbidities varied significantly between the two viral conditions.
Patients with MERS-CoV had 2-fold higher rates of obesity (P>0.05)
and 3-fold higher combined frequencies of cardiovascular diseases,
hypertension, and cardio-artillery diseases (P<0.05) (Tables 1 and 2).
The varying rates of comorbidities between H1N1 and MERS-CoV cases
may relate to their different patterns of regional spread. Cardiovascular
diseases are highly prevalent in the Middle East67 than in many regions
of the world.67,68 This observation also applies to obesity, although the
lower prevalence of obesity in males from the Arabian Peninsula versus
females69 and their higher predominance in MERS-CoV patients (see
above) together may have been combined to render the occurrence of
obesity in MERS-CoV non-significantly different from that in H1N1.
The increased risk of developing severe H1N1 and MERS-CoV compli-
cations in people with underlying chronic diseases was similarly
reported in seasonal influenza. A recent study noted that, compared to
subjects with no comorbidities, severe cases of influenza are more like-
ly to manifest with obesity (OR for mortality 2.74, 95%CI: 1.56-4.80),
cardiovascular diseases (2.92, 1.76-4.86), hypertension (1.49, 1.10-
2.01) and neuromuscular disease (2.68, 1.91-3.75).70 More studies
examining the link between SARI and metabolic syndrome-related
complications such as obesity and cardiovascular conditions are need-
ed to evaluate their contribution to the severity of infectious diseases.
The overall proportion of diabetes was ~4-fold higher in MERS-CoV
cases (54%) than in their H1N1 counterparts (15%) (Figures 3 and 4).
In agreement, odds ratio for severe H1N1 in diabetic subjects (ranging
from 2.2 to 4.4)16,19,23,30 was >3-fold lower than for severe MERS-CoV
(OR ranging from 7.2 to 15.7).9,40 Although at varying extents, these
findings implicate diabetes as a risk factor for sever MERS-CoV and
H1N1. One reason for this difference may relate to the higher average
age of MERS-CoV cases given that older age is a known risk factor for
type 2 diabetes.71 Although in younger Middle Eastern populations
rates of diabetes and its risk factors67 are higher than those in older
populations, the disease prevalence has increased across all age groups
rather than just in older adults in the region.72 Another possible expla-
nation can be attributed to the high prevalence of diabetes in the
Middle East and the Arabian Peninsula67 - where MERS-CoV originated
and spread - compared to its prevalence in other world regions.68
Similar increased rates of tuberculosis were noted in regions with high
diabetes prevalence.73 Additionally, subgroup analysis by region
demonstrated that diabetes frequency in H1N1 cases from Asia and
North America is ~2-fold higher than in those from Europe and South
America (Table 3). This coincides with the high prevalence of diabetes
in Asia and North America (~12%) compared to Europe or South and
Central America (~9%).74 However, despite the lines of evidence sug-
gesting an influence of the region of viral spread on diabetes propor-
tion in the severe cases of SARI, the rate of diabetes in MERS-CoV was
still ~3-fold higher than that in the H1N1 cases from Asia (17.6%, 95%
CI: 12.1-23.1; P<0.001; Table 3) - where diabetes rates are comparable
to those in the regions of MERS-CoV. This observation suggests that
the higher prevalence of diabetes in MERS-CoV cases than in H1N1,
may not be simply related to the regional differences in the viral spread
and that an etiologic role of diabetes in severe MERS-CoV cases may
exist distinctive from that in H1N1.
Diabetes can impair the innate immune system75 and render indi-
viduals more susceptible to a range of infectious diseases and severe
illnesses.13,75,76 For example, during seasonal influenza outbreaks,
compared to healthy subjects, diabetic patients were shown to have 6-
fold higher risk of becoming critically ill and acquire hospitalization
with 4-fold increased rates of pneumonia-related hospitalizations and
a 3-fold elevated likelihood of dying of complications.77 Diabetes share
several common features with infectious disorders and its complication
such as the endothelial dysfunction, the pro-inflammatory state and the
attenuation of innate immune response.75 The cytokine overload relat-
ed to the Th1 (microbicidal action of IFN-) to Th2 (anti-inflammatory
IL-4, -5, -10 and -13) shift in severe viral infection when accompanied
by the increased cytokine levels arising from diabetes, both can be
detrimental to the endothelium and lead to a range of subsequent com-
plications.78 Dampened innate immunity and the shift from Th1 to Th2
responses were implicated in linking the high prevalence of allergy
observed in fatal viral infections, e.g., Dengue fever.79 Furthermore,
diabetes can impair macrophage and lymphocyte functions with a sub-
sequent status of reduced immune response76 where individuals
become at increased risk of severe infectious disease outcome. In sup-
port, diabetes-associated hyperglycemia and cellular insulinopenia are
known to impair macrophage and lymphocyte functions with a subse-
quent status of reduced immune response.76 Furthermore, levels of
HbA1c ≥9% were linked to a 60% increased risk of pneumonia-related
complications and hospitalization due to a lower immune response.80
Host defense to infection is largely mediated by cellular immunity and
the synthesis of related cytokines, such as IFN-  and interleukins, is
downregulated in diabetes.75,81
The present study has several limitations. Inspection of the funnel
plot (Figure 2) and the Egger’s test indicates that publication bias may
have been derived from the small-study effect, i.e., the possibility of
including small studies with spuriously overstated estimates while
ignoring those without statistically significant effects that may have a
lower possibility of being published. Furthermore, the identified
reports have shown 8-fold among-studies variance in the diabetes pro-
portion for H1N1 (0.04-0.35; Figure 3) and MERS-CoV (0.1-0.8, Figure
4) cases. These inter-study differences may have contributed to the sig-
nificant heterogeneity observed in our report. Additional sources of
heterogeneity may relate to the large variation among studies in the
sample size (19 to 70,000 H1N1 cases and 5 to 161 MERS-CoV patients)
or the ethnic diversity of the study populations particularly within the
H1N1 studies (collected from 14 counties). Furthermore, heteroge-
neous methodologies due to different study designs may have influ-
enced the inter-study variation. This observation may levy some limita-
tions on the estimated contribution of diabetes to severe H1N1 and
MERS-CoV cases and render our results as a guide to generate more
accurate estimates for national or international intervention strategies
for severe SARI conditions in diabetic subjects. Furthermore, although
the prevalence of diabetes is 15% in severe H1N1 cases and 54% in
MERS-CoV, it may not implicate causality and warrants further studies
to identify the nature and extent of the coexistence between diabetes
and each of the two respiratory infections. Another limitation is the low
number of MERS-CoV cases and the narrow geographic region from
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which it was recruited, compared to the H1N1 cases that rendered sub-
group analysis (by region) unattainable for MERS-CoV cases. This par-
ticular limitation may add more weight to the suggestion stipulating
that the difference in diabetes prevalence between H1N1 and MERS-
CoV can be attributable to the regional difference in spread. The small
number of MERS-CoV studies highlights the need to develop interna-
tional collaborations that include cases from countries other than those
in the Arabian Peninsula, e.g., from Korea where a few recent cases
have been emerged recently. A single study44 has examined MERS-CoV
cases pooled from various countries but the findings were still limited
by the small population size. The reports identified in the present study
did not distinguish between the prevalence of type 1 and/or type 2 dia-
betes in H1N1 or MERS-CoV cases. With the exception of three studies
(only in the H1N1 - but not MERS-CoV),14,17,35 all the identified reports
have combined both types of diabetes despite their different character-
istics, etiological factors and clinical features. Cortes Garcia et al.,14
and Koegelenberg et al.,35 have clearly stated that the diabetic cases in
their H1N1 series as type 2 cases. Jimenez-Garcia et al.,17 on the other
hand, compared the demographic characteristics, underlying medical
conditions and in-hospital case fatality risk (CFR) in the type 1 (preva-
lence 0.8%) and type 2 (prevalence 8.4%) diabetic patients and report-
ed a ~2-fold higher CFR in type 2 cases than type 1.17 Given this paucity
of information, it was challenging to distinguish between the two types
of diabetes for their role in viral disease severity and complication.
Conclusions
In conclusion, the present study provides some evidence of a greater
prevalence of diabetes to MERS-CoV severity compared to H1N1. If this
relationship is causal, however, the substantial proportion of diabetes
in each of the two infections suggests that introducing effective strate-
gies for diabetes prevention may reduce the severity of a significant
number of SARI conditions. Specific systematic vaccination interven-
tion strategies against SARI diseases should be also considered for
patients with metabolic syndrome and related disorders such as dia-
betes, obesity and cardiovascular conditions.82 This should be viewed
as a key public health strategy in preventing SARI-associated morbidity
and mortality.83 During the 1957–58 pandemic and in response to sub-
stantial morbidity and mortality, the US Surgeon General recommend-
ed annual influenza vaccination for individuals with chronic debilitat-
ing disease, people aged ≥65 years and pregnant women.84 For these
high-risk groups, the first recommendation of national universal sea-
sonal influenza vaccination was established in 2010 by the Advisory
Committee on Immunization Practices (ACIP).85 Recently, influenza
vaccination was demonstrated to be associated with preventing all-
cause hospitalization in infected subjects.86 However, despite numer-
ous recommendations from several public health organizations across
the world (e.g., CDC, WHO, etc.) to administer SARI vaccines (e.g.,
influenza) annually to diabetic patients, vaccination rate in this vulner-
able sub-population remains low.87-89 The current level of vaccination
falls far short of the 2010 national health objectives call for a 90% rate
to all elderly people (≥65 years of age) and 60% for younger people who
have risk factors (e.g., diabetes).88 The prevalence of chronic diseases
is rising in middle- and low-income countries as populations age and
lifestyles and diets change. Further studies are being undertaken to
evaluate the prevalence of other comorbidities in H1N1 and MERS-CoV.
Subsequent introduction of effective public health vaccination inter-
vention approaches and strategies is necessary to improve the protec-
tion against SARI in subjects with chronic disorders such as diabetes,
obesity and cardiovascular conditions. 
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